MCID: DBT006
MIFTS: 48

Diabetic Macular Edema

Categories: Eye diseases

Aliases & Classifications for Diabetic Macular Edema

MalaCards integrated aliases for Diabetic Macular Edema:

Name: Diabetic Macular Edema 12 55 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9191
ICD9CM 35 362.07
SNOMED-CT 68 312912001
UMLS 73 C0730285

Summaries for Diabetic Macular Edema

MalaCards based summary : Diabetic Macular Edema is related to macular retinal edema and macular holes. An important gene associated with Diabetic Macular Edema is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Pioglitazone and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Diabetic Macular Edema

Diseases related to Diabetic Macular Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 31.4 ICAM1 IL6 PRKCB SERPINF1 VEGFA
2 macular holes 30.2 CCL2 SERPINF1 VEGFA
3 retinal vein occlusion 30.1 CCL2 IL6 SERPINF1 VEGFA
4 macular degeneration, age-related, 1 30.0 CCL2 FGF2 SERPINF1 VEGFA
5 ischemia 29.1 EPO ICAM1 NOS3 VEGFA
6 sleep apnea 28.8 ICAM1 IL6 NOS3 VEGFA
7 microvascular complications of diabetes 1 28.0 CCL2 FGF2 ICAM1 SERPINF1 SST VEGFA
8 diabetes mellitus 28.0 EPO IL6 NOS3 SST VEGFA
9 microvascular complications of diabetes 5 27.8 FGF2 ICAM1 NOS3 PRKCB SERPINF1 TEK
10 critical limb ischemia 10.7 IL6 VEGFA
11 retinitis 10.7
12 spinal disease 10.7 IL6 VEGFA
13 vibrio vulnificus infection 10.7 EPO IL6
14 diabetic cataract 10.6 SERPINF1 VEGFA
15 primary effusion lymphoma 10.6 IL6 VEGFA
16 arteriovenous fistula 10.6 EPO IL6
17 endophthalmitis 10.6 ICAM1 VEGFA
18 chronic eosinophilic pneumonia 10.5 ICAM1 IL6
19 herpes simplex virus keratitis 10.5 CCL2 ICAM1
20 pyogenic granuloma 10.5 TEK VEGFA
21 endotheliitis 10.5
22 acute monoblastic leukemia 10.5 EPO IL6
23 denture stomatitis 10.5 CCL2 IL6
24 anterior uveitis 10.5 CCL2 IL6
25 capillary hemangioma 10.5 TEK VEGFA
26 spindle cell sarcoma 10.5 IL6 VEGFA
27 central retinal vein occlusion 10.5 IL6 SERPINF1 VEGFA
28 eales disease 10.5 IL6 SERPINF1 VEGFA
29 hypersensitivity reaction type iii disease 10.4 ICAM1 IL6
30 acute proliferative glomerulonephritis 10.4 CCL2 ICAM1
31 retinal vascular disease 10.4 ICAM1 SERPINF1 VEGFA
32 radiation proctitis 10.4 FGF2 VEGFA
33 stachybotrys chartarum 10.4 CCL2 IL6
34 retinal vascular occlusion 10.4 CCL2 VEGFA
35 poems syndrome 10.4 EPO IL6 VEGFA
36 laryngitis 10.4 FGF2 IL6
37 aging 10.3
38 cataract 10.3
39 idiopathic interstitial pneumonia 10.3 CCL2 ICAM1 VEGFA
40 endometriosis 10.3 CCL2 IL6 VEGFA
41 cortical thymoma 10.3 ICAM1 SST
42 post-thrombotic syndrome 10.2 CCL2 ICAM1 IL6
43 alcoholic hepatitis 10.2 CCL2 ICAM1 IL6
44 autoinflammation, lipodystrophy, and dermatosis syndrome 10.2 CCL2 ICAM1 IL6
45 leukostasis 10.2 ICAM1 VEGFA
46 angiomatous meningioma 10.2 FGF2 VEGFA
47 peritonitis 10.2 CCL2 ICAM1 IL6
48 respiratory system disease 10.2 CCL2 ICAM1 IL6
49 exudative vitreoretinopathy 1 10.2 EPO TEK VEGFA
50 pericardial effusion 10.2 FGF2 IL6 VEGFA

Graphical network of the top 20 diseases related to Diabetic Macular Edema:



Diseases related to Diabetic Macular Edema

Symptoms & Phenotypes for Diabetic Macular Edema

MGI Mouse Phenotypes related to Diabetic Macular Edema:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 TEK VEGFA FGF2 PRKCB ICAM1 SERPINF1
2 homeostasis/metabolism MP:0005376 10.07 TEK VEGFA FGF2 PRKCB ICAM1 SST
3 hematopoietic system MP:0005397 10.06 TEK VEGFA FGF2 PRKCB ICAM1 SERPINF1
4 immune system MP:0005387 9.97 VEGFA NOS3 PRKCB ICAM1 SERPINF1 SST
5 digestive/alimentary MP:0005381 9.91 SST VEGFA NOS3 ICAM1 SERPINF1 IL6
6 nervous system MP:0003631 9.81 TEK VEGFA NOS3 FGF2 PRKCB ICAM1
7 muscle MP:0005369 9.8 TEK VEGFA FGF2 ICAM1 IL6 EPO
8 skeleton MP:0005390 9.5 SST VEGFA NOS3 FGF2 SERPINF1 IL6
9 vision/eye MP:0005391 9.17 TEK VEGFA NOS3 FGF2 ICAM1 SERPINF1

Drugs & Therapeutics for Diabetic Macular Edema

Drugs for Diabetic Macular Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
5
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
6
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
7
Linagliptin Approved Phase 4 668270-12-0 10096344
8
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
9
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
10
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
11
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
12
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3 378-44-9 9782
13
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2 78281-72-8 151075
14
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 67-73-2 6215
15 Homatropine Approved Phase 4 87-00-3
16
Verteporfin Approved, Investigational Phase 4 129497-78-5
17
Glimepiride Approved Phase 4 93479-97-1 3476
18
Empagliflozin Approved Phase 4 864070-44-0
19
Benzocaine Approved, Investigational Phase 4,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
20 tannic acid Approved, Nutraceutical Phase 4,Phase 1,Phase 2
21
Lactitol Investigational Phase 4 585-86-4 3871
22
Bromfenac Approved July 1997 Phase 4,Phase 1 91714-94-2 60726
23
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
24 triamcinolone acetonide Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
26 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28
protease inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
29 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Glycoside Hydrolase Inhibitors Phase 4
33 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
35 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
37 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Dipeptidyl-Peptidase IV Inhibitors Phase 4
39 Triamcinolone diacetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Triamcinolone hexacetonide Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
47 Hypoglycemic Agents Phase 4,Not Applicable
48 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Antibodies Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 426)
# Name Status NCT ID Phase Drugs
1 Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Unknown status NCT02633852 Phase 4 Aflibercept
2 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4 Ranibizumab
3 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
4 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Unknown status NCT02684084 Phase 4 Ozurdex;Lucentis
5 The Endurance 1 Trial Unknown status NCT02297204 Phase 4 aflibercept 2.0 mg
6 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
7 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
8 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
9 To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
10 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
11 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
12 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
13 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
14 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
15 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
16 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
17 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
18 A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Completed NCT02359526 Phase 4 IlUVIEN
19 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
20 Topical Nepafenac as Supplement for Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
21 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
22 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial) Completed NCT02368756 Phase 4 Aflibercept
23 Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
24 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
25 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4 Bromefenac;Blink
26 Unilateral Bevacizumab for Bilateral Diabetic Macular Edema Completed NCT00496405 Phase 4 bevacizumab
27 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
28 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
29 Ranibizumab "Treat and Extend" in Diabetic Macular Edma Completed NCT01297569 Phase 4 Ranibizumab
30 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4 Ranibizumab
31 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
32 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
33 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Completed NCT02503540 Phase 4 Aflibercept
34 Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial Completed NCT02299336 Phase 4 Aflibercept
35 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticost Completed NCT02472366 Phase 4 ILUVIEN
36 Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
37 Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation Completed NCT01223612 Phase 4 Ranibizumab
38 Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema Completed NCT02366468 Phase 4 0.5 mg ranibizumab;0.5 mg ranibizumab
39 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
40 Comparison of VA Guided Versus OCT Guided TER Using Ranibizumab for Diabetic Macular Edema (AVOCT Study) Recruiting NCT03394573 Phase 4 Ranibizumab Injection
41 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Recruiting NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
42 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema Recruiting NCT02441907 Phase 4 aflibercept
43 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Recruiting NCT02924987 Phase 4 Aflibercept Injection
44 Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab Recruiting NCT02665689 Phase 4 ranibizumab
45 Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection Recruiting NCT03453281 Phase 4 Aflibercept Injection [Eylea]
46 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Recruiting NCT03097068 Phase 4 Lucentis
47 Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) Recruiting NCT02788877 Phase 4 aflibercept
48 Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab Recruiting NCT02559180 Phase 4 aflibercept
49 IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab Recruiting NCT03340610 Phase 4 Alflibercept
50 Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema Recruiting NCT02985242 Phase 4 Empagliflozin;Glimepiride;Empagliflozin placebo;Glimepiride placebo

Search NIH Clinical Center for Diabetic Macular Edema

Genetic Tests for Diabetic Macular Edema

Anatomical Context for Diabetic Macular Edema

MalaCards organs/tissues related to Diabetic Macular Edema:

41
Eye, Endothelial, Retina, Testes, Bone, Monocytes

Publications for Diabetic Macular Edema

Articles related to Diabetic Macular Edema:

(show top 50) (show all 710)
# Title Authors Year
1
Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema. ( 29977811 )
2018
2
Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema. ( 29850202 )
2018
3
Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice. ( 29386883 )
2018
4
Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. ( 29283132 )
2018
5
Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Does Flavor Matter? ( 29392302 )
2018
6
Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study). ( 29916263 )
2018
7
Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting. ( 29850205 )
2018
8
Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema. ( 29316563 )
2018
9
One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema. ( 29265939 )
2018
10
Intravitreal dexamethasone implants for diabetic macular edema. ( 29375995 )
2018
11
Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach. ( 29882421 )
2018
12
Multimodal Imaging in Diabetic Macular Edema. ( 29376234 )
2018
13
Real-life experience of ranibizumab for diabetic macular edema in Taiwan. ( 29926364 )
2018
14
Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. ( 29336896 )
2018
15
Choroidal Thickness in Diabetic Macular Edema Compared to Normal Controls. ( 29944846 )
2018
16
Early Retinal and Choroidal Coat Thickness Changes After Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema. ( 29866639 )
2018
17
Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema. ( 29896154 )
2018
18
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment - reply to the letter to the editor. ( 29368041 )
2018
19
Pharmacology of Corticosteroids for Diabetic Macular Edema. ( 29297055 )
2018
20
Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema. ( 29943100 )
2018
21
Apelin-13 Is an Early Promoter of Cytoskeleton and Tight Junction in Diabetic Macular Edema via PI-3K/Akt and MAPK/Erk Signaling Pathways. ( 29850504 )
2018
22
Prevalence of diabetic retinopathy and diabetic macular edema in a primary care-based teleophthalmology program for American Indians and Alaskan Natives. ( 29924846 )
2018
23
Evaluation of Navigated Laser Photocoagulation (Navilas 577+) for the Treatment of Refractory Diabetic Macular Edema. ( 29854426 )
2018
24
ILUVIEN<sup>Ar</sup> technology in the treatment of center-involving diabetic macular edema: a review of the literature. ( 29943691 )
2018
25
Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections. ( 29922890 )
2018
26
Oral administration of a curcumin-phospholipid formulation (MerivaAr) for treatment of chronic diabetic macular edema: a pilot study. ( 29917217 )
2018
27
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. ( 29392288 )
2018
28
Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab. ( 29403260 )
2018
29
Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema. ( 29850199 )
2018
30
Association Between Soluble CD14 in the Aqueous Humor and Hyperreflective Foci on Optical Coherence Tomography in Patients With Diabetic Macular Edema. ( 29392317 )
2018
31
Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. ( 29970221 )
2018
32
Evaluation of Vitrectomy with Planned Foveal Detachment as Surgical Treatment for Refractory Diabetic Macular Edema with or without Vitreomacular Interface Abnormality. ( 29854429 )
2018
33
A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. ( 29847672 )
2018
34
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. ( 29353345 )
2018
35
An exudate detection method for diagnosis risk of diabetic macular edema in retinal images using feature-based and supervised classification. ( 29318442 )
2018
36
Disorganization of Inner Retina and Outer Retinal Morphology in Diabetic Macular Edema. ( 29327033 )
2018
37
Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190a88A/g intravitreal implant in people with diabetic macular edema. ( 28881149 )
2017
38
Health-economic evaluation of fluocinolone acetonide 190a88A/g implant in people with diabetic macular edema. ( 28881146 )
2017
39
Evidence-Based Treatment of Diabetic Macular Edema. ( 28060586 )
2017
40
Efficacy of 0.2a88I1g/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. ( 28085139 )
2017
41
Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema. ( 28819567 )
2017
42
The Distribution of Leakage on Fluorescein Angiography in Diabetic Macular Edema: A New Approach to Its Etiology. ( 28796876 )
2017
43
Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. ( 28841827 )
2017
44
Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. ( 28061854 )
2017
45
INTEGRITY OF OUTER RETINAL LAYERS AFTER RESOLUTION OF CENTRAL INVOLVED DIABETIC MACULAR EDEMA. ( 28092342 )
2017
46
Combined Intravitreal Dexamethasone Implant And Micropulse Yellow Laser For Treatment Of Anti-VEGF Resistant Diabetic Macular Edema. ( 28839510 )
2017
47
Plasma Kallikrein Inhibitors for the Treatment of Retinal Vascular Permeability Associated with Diabetic Retinopathy and Diabetic Macular Edema. ( 28835783 )
2017
48
Combined Phacoemulsification and Intravitreal Dexamethasone Implant (OzurdexAr) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema. ( 28884024 )
2017
49
Foveal Microstructure Analysis in Eyes with Diabetic Macular Edema Treated with Vitrectomy. ( 28808926 )
2017
50
Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol. ( 29349082 )
2017

Variations for Diabetic Macular Edema

Expression for Diabetic Macular Edema

Search GEO for disease gene expression data for Diabetic Macular Edema.

Pathways for Diabetic Macular Edema

Pathways related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 CCL2 EPO IL6 NOS3 PRKCB SERPINF1
2
Show member pathways
13.36 CCL2 EPO FGF2 IL6 TEK VEGFA
3
Show member pathways
13.26 CCL2 FGF2 IL6 NOS3 PRKCB TEK
4
Show member pathways
13.2 CCL2 FGF2 ICAM1 IL6 TEK VEGFA
5
Show member pathways
13.14 FGF2 IL6 NOS3 PRKCB TEK VEGFA
6
Show member pathways
12.78 EPO FGF2 IL6 NOS3 TEK VEGFA
7 12.71 EPO FGF2 IL6 PRKCB VEGFA
8
Show member pathways
12.67 CCL2 ICAM1 IL6 PRKCB
9
Show member pathways
12.65 FGF2 IL6 PRKCB VEGFA
10 12.64 FGF2 PRKCB TEK VEGFA
11
Show member pathways
12.61 FGF2 PRKCB TEK VEGFA
12
Show member pathways
12.53 CCL2 ICAM1 NOS3 PRKCB VEGFA
13
Show member pathways
12.43 CCL2 FGF2 IL6 NOS3 TEK
14
Show member pathways
12.37 FGF2 ICAM1 IL6 PRKCB VEGFA
15
Show member pathways
12.19 CCL2 ICAM1 NOS3 PRKCB VEGFA
16
Show member pathways
12.11 FGF2 NOS3 PRKCB VEGFA
17
Show member pathways
12.1 CCL2 PRKCB VEGFA
18 12.07 IL6 SST VEGFA
19 11.96 FGF2 IL6 VEGFA
20
Show member pathways
11.96 CCL2 FGF2 ICAM1 IL6
21 11.95 CCL2 ICAM1 NOS3 VEGFA
22 11.9 CCL2 ICAM1 IL6
23
Show member pathways
11.84 IL6 NOS3 PRKCB
24 11.83 CCL2 ICAM1 IL6
25 11.78 CCL2 FGF2 ICAM1 IL6 VEGFA
26 11.68 CCL2 FGF2 NOS3 TEK
27 11.61 CCL2 ICAM1 IL6 TEK VEGFA
28 11.58 CCL2 FGF2 IL6
29
Show member pathways
11.57 ICAM1 IL6 VEGFA
30 11.49 EPO NOS3 VEGFA
31 11.44 CCL2 ICAM1 IL6
32 11.43 CCL2 ICAM1 IL6
33 11.43 EPO IL6 NOS3 PRKCB TEK VEGFA
34 11.35 EPO FGF2 IL6 VEGFA
35 11.26 ICAM1 IL6 PRKCB
36 11.23 CCL2 IL6 NOS3
37 11.1 FGF2 VEGFA
38 11.1 CCL2 ICAM1 IL6 NOS3 PRKCB VEGFA
39 11.08 CCL2 ICAM1
40 10.94 CCL2 VEGFA
41 10.86 CCL2 ICAM1
42 10.84 FGF2 NOS3 TEK VEGFA

GO Terms for Diabetic Macular Edema

Cellular components related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 CCL2 EPO FGF2 IL6 SERPINF1 SST
2 extracellular space GO:0005615 9.23 CCL2 EPO FGF2 ICAM1 IL6 SERPINF1

Biological processes related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.9 EPO FGF2 IL6 VEGFA
2 cytokine-mediated signaling pathway GO:0019221 9.77 CCL2 FGF2 ICAM1 IL6 VEGFA
3 regulation of cell shape GO:0008360 9.74 CCL2 ICAM1 VEGFA
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.73 ICAM1 IL6 PRKCB
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.72 CCL2 EPO FGF2 ICAM1 TEK
6 cellular response to lipopolysaccharide GO:0071222 9.71 CCL2 ICAM1 IL6
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.65 ICAM1 IL6 VEGFA
8 angiogenesis GO:0001525 9.65 CCL2 FGF2 NOS3 TEK VEGFA
9 positive regulation of endothelial cell proliferation GO:0001938 9.63 FGF2 TEK VEGFA
10 regulation of signaling receptor activity GO:0010469 9.63 CCL2 EPO FGF2 IL6 SST VEGFA
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 EPO IL6 VEGFA
12 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.59 FGF2 TEK
13 positive regulation of sprouting angiogenesis GO:1903672 9.58 FGF2 VEGFA
14 positive regulation of focal adhesion assembly GO:0051894 9.58 TEK VEGFA
15 positive regulation of blood vessel endothelial cell migration GO:0043536 9.58 FGF2 NOS3 VEGFA
16 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.55 PRKCB VEGFA
17 cell migration involved in sprouting angiogenesis GO:0002042 9.52 FGF2 VEGFA
18 negative regulation of calcium ion transport GO:0051926 9.51 ICAM1 NOS3
19 response to acidic pH GO:0010447 9.49 SERPINF1 SST
20 response to hypoxia GO:0001666 9.35 EPO ICAM1 PRKCB TEK VEGFA
21 positive regulation of angiogenesis GO:0045766 9.02 FGF2 NOS3 PRKCB TEK VEGFA

Molecular functions related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 FGF2 IL6 VEGFA
2 cytokine activity GO:0005125 9.02 CCL2 EPO FGF2 IL6 VEGFA

Sources for Diabetic Macular Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....